# Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency

> **NCT04706013** · PHASE3 · RECRUITING · sponsor: **Medicure** · enrollment: 15 (estimated)

## Conditions studied

- Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency

## Interventions

- **DRUG:** Pyridoxal Phosphate

## Key facts

- **NCT ID:** NCT04706013
- **Lead sponsor:** Medicure
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-16
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04706013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04706013, "Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04706013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*